Phase II randomized clinical trial of Pazopanib alone and Pazopanib plus Gemcitabine in relapsed or metastatic soft tissue sarcoma.
Phase of Trial: Phase II
Latest Information Update: 30 Jun 2017
At a glance
- Drugs Pazopanib (Primary) ; Gemcitabine
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- Acronyms PAPAGEMO
- 09 Jul 2016 Status changed from recruiting to completed.
- 07 Jun 2016 Primary endpoint (Progression-free survival rate) has been met, according to a results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology